INDIANAPOLIS, June 5, 2024
/PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) announced today
that Anat Ashkenazi has resigned as chief financial officer to
pursue a career opportunity outside of the pharmaceutical
industry.
"On behalf of our board of directors, leadership team and
employees, I would like to thank Anat for her 23 years of
outstanding service to our company," said David A. Ricks, Lilly's chair and CEO. "During
her last three years as Lilly's CFO, we have experienced tremendous
growth and laid the groundwork to help us reach even more patients
with our medicines. I want to personally thank Anat for her
partnership, friendship, and leadership of our financial
organization and to wish her well in her new role."
Prior to serving as Lilly's CFO, Ms. Ashkenazi was senior vice
president, controller, and chief financial officer of Lilly
Research Laboratories. In this role, she oversaw the CFOs of the
company's commercial businesses, as well as those for research and
development, manufacturing and quality, and G&A functions. She
also led the corporate strategy team and business transformation
office. Previously, she served as CFO for several of the company's
global business areas.
Ms. Ashkenazi will continue to serve at full capacity in her
role and as a member of Lilly's Executive
Committee through July
2024. An internal and external search for her
successor is actively underway.
About Lilly
Lilly is a medicine company turning science into healing to make
life better for people around the world. We've been pioneering
life-changing discoveries for nearly 150 years, and today, our
medicines help more than 51 million people across the globe.
Harnessing the power of biotechnology, chemistry and genetic
medicine, our scientists are urgently advancing new discoveries to
solve some of the world's most significant health challenges:
redefining diabetes care; treating obesity and curtailing its most
devastating long-term effects; advancing the fight against
Alzheimer's disease; providing solutions to some of the most
debilitating immune system disorders; and transforming the most
difficult-to-treat cancers into manageable diseases. With each step
toward a healthier world, we're motivated by one thing: making life
better for millions more people. That includes delivering
innovative clinical trials that reflect the diversity of our world
and working to ensure our medicines are accessible and affordable.
To learn more, visit Lilly.com and Lilly.com/news, or follow
us on Facebook, Instagram and LinkedIn. C-LLY
Lilly Cautionary Statement Regarding
Forward-Looking Statements
This press release contains certain forward-looking statements
regarding leadership changes and expectations for the future. All
statements other than statements of historical fact are statements
that could be deemed forward-looking statements within the meaning
of Section 27A of the Securities Act of 1933 and Section 21E of the
Securities Exchange Act of 1934. The word "will" and similar
expressions are intended to identify forward-looking statements.
Actual results may differ materially due to various factors. The
following include some but not all of the factors that could cause
actual results or events to differ materially from those
anticipated, including the significant costs and uncertainties in
the pharmaceutical research and development process, including with
respect to the timing and process of obtaining regulatory
approvals; the impact and outcome of acquisitions and business
development transactions and related costs; the expiration of
intellectual property protection for certain of the company's
products and competition from generic and/or biosimilar products;
the company's ability to protect and enforce patents and other
intellectual property; changes in patent law or regulations related
to data package exclusivity; competitive developments affecting
current products and the company's pipeline; market uptake of
recently launched products; information technology system
inadequacies, breaches, or operating failures; unauthorized access,
disclosure, misappropriation, or compromise of confidential
information or other data stored in the company's information
technology systems, networks, and facilities, or those of third
parties with whom the company shares its data; the impact of global
macroeconomic conditions, trade disruptions, disputes, unrest, war,
regional dependencies, or other costs, uncertainties and risks
related to engaging in business globally; unexpected safety or
efficacy concerns associated with the company's products;
litigation, investigations, or other similar proceedings involving
past, current, or future products or commercial activities as the
company is largely self-insured; issues with product supply and
regulatory approvals stemming from manufacturing difficulties,
disruptions, or shortages, including as a result of
unpredictability and variability in demand, labor shortages,
third-party performance, quality, or regulatory actions related to
our facilities; dependence on certain products for a significant
percentage of our total revenue and an increasingly consolidated
supply chain; reliance on third-party relationships and outsourcing
arrangements; the impact of public health outbreaks, epidemics, or
pandemics, such as the COVID-19 pandemic; regulatory changes or
other developments; regulatory actions regarding operations and
products; continued pricing pressures and the impact of actions of
governmental and private payers affecting pricing of, reimbursement
for, and access to pharmaceuticals; devaluations in foreign
currency exchange rates or changes in interest rates and inflation;
changes in tax law, tax rates, or events that differ from the
company's assumptions related to tax positions; asset impairments
and restructuring charges; changes in accounting and reporting
standards promulgated by the Financial Accounting Standards
Board and the Securities and Exchange Commission (SEC); regulatory
compliance problems or government investigations; and actual or
perceived deviation from environmental-, social-, or
governance-related requirements or expectations. For additional
information about the factors that could cause actual results or
events to differ materially from forward-looking statements, please
see the company's latest Form 10-K and subsequent Forms 8-K and
10-Q filed with the SEC. You should not place undue reliance on
forward-looking statements, which speak only as of the date of this
release. Except as is required by law, the company expressly
disclaims any obligation to publicly release any revisions to
forward-looking statements to reflect events after the date of this
release.
Refer to:
|
Tarsis Lopez;
tarsis.lopez@lilly.com; (224) 406-2746 (Media)
|
|
Joe
Fletcher; jfletcher@lilly.com; (317) 296-2884
(Investors)
|
View original content to download
multimedia:https://www.prnewswire.com/news-releases/lilly-announces-departure-of-anat-ashkenazi-chief-financial-officer-302163882.html
SOURCE Eli Lilly and Company